Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

@inproceedings{Daud2010PharmacokineticpharmacodynamicAO,
  title={Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma},
  author={Adil I Daud and Christine Shuyu Xu and W J Hwu and Patricia Urbas and Stephanie Andrews and Nicholas E J Papadopoulos and Leslie Carstensen Floren and Antoine Yver and Ronald C Deconti and Vernon K. Sondak},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2010}
}
High-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma. For PK analysis, 32 patients received peginterferon α-2b 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance). PK profiles were determined at weeks 1, 8, and 12… CONTINUE READING
8 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Interferon- as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials

  • K Wheatley, N Ives, A Eggermont
  • J Clin Oncol (Meeting
  • 2007
1 Excerpt

with PEG Intron : pharmacokinetic pro W le and dosing guidelines for an improved interferon - alpha - 2 b formulation

  • P Tagliaferri, M Caraglia, A Budillon
  • 2005

Similar Papers

Loading similar papers…